[ad_1]
AAfter more than five years of litigation, Bayer (BAYRY) and Johnson & Johnson (JNJ) agreed to shell out $ 775 million to settle approximately 25,000 lawsuits for claims they did not warn about side effects associated with the anticoagulant Xarelto, which companies market jointly. .
The regulation, which will be split equally among drug manufacturers, resolves federal and national cases alleging that companies are minimizing the potentially lethal risks of internal bleeding and aggressively marketing the drug as an alternative to warfarin for those seeking avoid blood clots. Neither company has acknowledged responsibility, though both have indicated that they have prevailed in six cases that have been judged.
Unlock this item by subscribing to STAT Plus and enjoy your first 30 days for free!
TO START
What is it?
STAT Plus is a premium subscription that offers scalable biopharmaceutical market coverage and in-depth scientific reports from a team with several decades of experience in the industry.
What is included?
- Authoritative coverage and biopharmaceutical analysis, interviews with industry pioneers, policy analysis and first examination of advanced laboratories and early stage research
- Subscriber Networking Events and Group Discussions Across the Country
- Monthly live subscriber discussions with our reporters and experts in the field
- Discounted tickets for industry events and early access to industry reports
[ad_2]
Source link